vTv Therapeutics of High Point has out-licensed worldwide development and commercialization rights to its potential kidney disease drug to a California biotech company in a deal that ultimately could be worth more than $150 million.
Read More
Thursday was not a good day for North Carolina life science companies. While BioDelivery Sciences reported a big profit, BioCryst, Aerie, TransEnterix, Chimerix and vTv Therapeutics all reported signifcant losses.
Read More
LabCorp, Liquidia, United Therapeutics, TransEnterix, Aerie Pharma and vTv Therapeutics are making headlines. Here’s the latest.
Read More
Semiconductor firm Qorvo, which is based in Greensboro, reported a Street-beating quarter on Thursday. But nearby vTv Therapeutics reported a loss.
Read More
vTv Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of clinical drug candidates for the treatment of Alzheimer’s disease, diabetes, and inflammatory disorders. On Thursday, it reported a loss of $4.4 million in its fourth quarter.
Read More
Altis Biosystems and Innovate Biopharmaceuticals are among a handful of companies that have raised millions in funding to kick off the new decade. Read more here.
Read More
vTv Therapeutics, a clinical-stage biopharmaceutical company that is developing a pipeline of clinical drug candidates for the treatment of Alzheimer’s disease, diabetes, and inflammatory disorders, has raised $2 million.
Read More
Based out of High Point, the firm is said to have a powerful pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases, including Alzheimer’s disease, diabetes and inflammation.
Read More
A High Point therapeutics firm focused on developing treatments for unmet medical needs has raised $1.5 million of an equity round targeted at $10 million.
Read More
